Telmisartan + Amlodipine
Teldipin contains two active substances - telmisartan and amlodipine. Both substances help control high blood pressure.
Teldipin is used, instead of taking separate medicines, to treat high blood pressure (hypertension) in patients who are already taking telmisartan and amlodipine in the same doses as in Teldipin.
If any of the above conditions apply to the patient, they should inform their doctor or pharmacist before taking Teldipin.
The patient should inform their doctor if they have or have had any of the following conditions or diseases:
The patient should inform their doctor before taking Teldipin:
If the patient experiences stomach pain, nausea, vomiting, or diarrhea after taking Teldipin, they should discuss this with their doctor. The doctor will decide on further treatment. The patient should not stop taking Teldipin on their own.
The patient should inform their doctor about pregnancy, suspected pregnancy, or planned pregnancy. It is not recommended to take Teldipin in early pregnancy and it should not be taken after the third month of pregnancy, as it may seriously harm the baby (see "Pregnancy").
In the event of planned surgery or anesthesia, the patient should inform their doctor about taking Teldipin.
Teldipin may be less effective in lowering blood pressure in black patients.
Teldipin is not recommended for children and adolescents under 18 years of age.
The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take. The doctor may recommend changing the dose of these medicines or taking other precautions. In some cases, it may be necessary to stop taking one of the medicines.
This is especially true for the following medicines taken with Teldipin:
The effect of Teldipin may be reduced when taken with non-steroidal anti-inflammatory drugs (NSAIDs, e.g., aspirin or ibuprofen) or corticosteroids.
Teldipin may lower blood pressure more when taken with other blood pressure-lowering medicines or may enhance the blood pressure-lowering effect of medicines that lower blood pressure as an additional effect (e.g., baclofen, amifostine). Additionally, blood pressure lowering may be enhanced by alcohol, barbiturates, opioids/narcotics, or antidepressants. The symptom is dizziness when standing up. If necessary, the patient should consult their doctor about adjusting the dose of another medicine they are taking while taking Teldipin.
The patient should not drink grapefruit juice or eat grapefruits while taking Teldipin, as grapefruits and grapefruit juice may increase the levels of the active substance amlodipine in the blood, which may cause unpredictable enhancement of the blood pressure-lowering effect of Teldipin. Additionally, blood pressure may be further lowered when drinking alcohol.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this medicine.
Pregnancy
The patient should inform their doctor about pregnancy, suspected pregnancy, or planned pregnancy. The doctor will usually recommend stopping Teldipin before planned pregnancy or as soon as pregnancy is confirmed and recommend another medicine instead of Teldipin. It is not recommended to take Teldipin in early pregnancy and it should not be taken after the third month of pregnancy, as it may seriously harm the baby if taken after 3 months of pregnancy.
Breastfeeding
The patient should tell their doctor about breastfeeding or intending to breastfeed. It is not recommended to take Teldipin while breastfeeding. The doctor may recommend another medicine if the patient wants to breastfeed, especially if the baby is a newborn or premature.
Amlodipine has been shown to pass into breast milk in small amounts.
Teldipin may impair the ability to drive and use machines. If the patient experiences nausea, dizziness, fatigue, or headache, they should not drive or operate machines and should contact their doctor immediately.
This medicine contains less than 1 mmol of sodium (23 mg) per tablet, which means that the medicine is considered "sodium-free".
This medicine should always be taken exactly as prescribed by the doctor or pharmacist. If the patient has any doubts, they should consult their doctor or pharmacist.
The recommended dose of Teldipin is one tablet per day.
The tablet should be swallowed with water, with or without food. The medicine should be taken every day at the same time. The patient should not take Teldipin with grapefruit juice.
It is important to continue taking Teldipin for as long as the doctor recommends.
If the patient accidentally takes too many tablets, they should immediately contact their doctor or pharmacist or go to the emergency department of the nearest hospital.
Taking too much of the medicine may cause a significant decrease in blood pressure. The patient may experience dizziness, a feeling of emptiness in the head, fainting, or weakness. In the event of a very significant decrease in blood pressure, shock may occur. The patient's skin may become cool and moist, and they may lose consciousness.
Up to 24-48 hours after taking the medicine, shortness of breath due to excessive fluid accumulation in the lungs (pulmonary edema) may occur.
If the patient forgets to take a dose, they should not worry. They should take the missed dose as soon as they remember, and then take the next doses at the usual time. If the tablet is not taken on one day, the patient should take the next dose the next day. The patient should not take a double dose to make up for the missed dose.
The doctor will decide how long the patient should take this medicine. If the patient stops taking the medicine earlier than recommended by the doctor, the disease may return.
If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.
Like all medicines, Teldipin can cause side effects, although not everybody gets them.
Side effects associated with TELMISARTAN:
Uncommon side effects(may affect up to 1 in 100 people):
Rare side effects(may affect up to 1 in 1,000 people):
Very rare side effects(may affect up to 1 in 10,000 people):
Frequency not known(frequency cannot be estimated from the available data)
*This phenomenon may be coincidental or related to a mechanism that has not yet been identified.
**There have been reports of progressive scarring of lung tissue during treatment with telmisartan.
The causal relationship between telmisartan and this condition has not been established.
Side effects associated with AMLODIPINE:
The following very common side effects have been reported. If any of these side effects bother the patient or persist for more than a week, they should consult their doctor.
Very common side effects(may affect more than 1 in 10 people):
The following common side effects have been reported. If any of these side effects bother the patient or persist for more than a week, they should consult their doctor.
Common side effects(may affect up to 1 in 10 people):
The following side effects have also been reported. If any of these side effects worsen or occur, the patient should inform their doctor or pharmacist.
Uncommon side effects(may affect up to 1 in 100 people):
Rare side effects(may affect up to 1 in 1,000 people):
Very rare side effects(may affect up to 1 in 10,000 people):
Frequency not known(frequency cannot be estimated from the available data):
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should inform their doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products:
Al. Jerozolimskie 181C, 02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
The medicine should not be taken after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
There are no special storage temperature requirements for this medicine.
The medicine should be stored in its original packaging to protect it from moisture.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Teldipin, 40 mg + 5 mg, tablets: light brown-yellow, round, biconvex tablets, with possible lighter and darker spots, with the marking N1 on one side. Tablet dimensions: diameter approximately 9 mm.
Teldipin, 40 mg + 10 mg, tablets: light orange, round, biconvex tablets, with possible lighter and darker spots, with the marking N2 on one side. Tablet dimensions: diameter approximately 9 mm.
Teldipin, 80 mg + 5 mg, tablets: light orange, oval, biconvex tablets, with possible lighter and darker spots, with the marking N3 on one side. Tablet dimensions: length approximately 17 mm.
Teldipin, 80 mg + 10 mg, tablets: light brown-yellow, oval, biconvex tablets, with possible lighter and darker spots, with the marking N4 on one side. Tablet dimensions: length approximately 17 mm.
Packaging:14, 28, 30, 56, 60, 84, 90, and 98 tablets in blisters in a cardboard box.
Not all pack sizes may be marketed.
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany
In order to obtain more detailed information on this medicine, the patient should contact the local representative of the marketing authorization holder:
KRKA-POLSKA Sp. z o.o.
ul. Równoległa 5
Czech Republic | Telmisartan/amlodipin Krka |
Poland | Teldipin |
02-235 Warsaw
Phone: 22 57 37 500
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.